{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-23-001809","form_type":"8-K","ticker":"CMMB","cik":"0001534248","company_name":"Chemomab Therapeutics Ltd.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.302425+00:00","generated_at":"2026-06-15T04:04:47.839339+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Chemomab Q1 net loss $8.8M; cash $32.8M; CM-101 Phase 2 NASH trial meets safety endpoint","bullets":["Net loss of $8.8M ($0.04 per share) vs $5.1M in Q1 2022; R&D expenses rose to $6.9M from $2.7M.","Cash, equivalents and short-term deposits $32.8M at March 31, 2023, down from $39.9M at Dec 31, 2022; runway extended through H1 2024.","CM-101 Phase 2 NASH liver fibrosis trial met primary safety endpoint; showed positive activity on fibrotic and inflammatory biomarkers.","FDA cleared IND for CM-101 Phase 2 systemic sclerosis trial; initial U.S. sites expected to open mid-2023.","Phase 2 PSC trial advancing with higher dose cohort; top-line data from double-blind portion expected H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-23-001809","json":"https://secwatch.observer/filing/0001178913-23-001809.json","markdown":"https://secwatch.observer/filing/0001178913-23-001809.md","text":"https://secwatch.observer/filing/0001178913-23-001809.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534248/000117891323001809/0001178913-23-001809-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534248/000117891323001809/zk2329704.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:04:47.839339+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"be8d34a5ba364dd8f3aca0c96622a36f0d622ad1","claim":"Chemomab Therapeutics Ltd. reported first quarter ended March 31, 2023 results: net income $8.8 million, EPS approximately $0.04 per basic and diluted ordinary share.","evidence_excerpt":"Net loss was $8.8 million, or a net loss of approximately $0.04 per basic and diluted ordinary share for the first quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891323001809/0001178913-23-001809-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"$8.8 million"},{"label":"EPS","value":"approximately $0.04 per basic and diluted ordinary share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}